ACTRN12618000519257
招募中
未知
SpeechATAX: A 2-arm, examiner-blinded, wait-list control group randomized controlled trial of intensive home based biofeedback driven speech rehabilitation in hereditary ataxia
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- Dysarthria
- 发起方
- The University of Melbourne
- 入组人数
- 100
- 状态
- 招募中
- 最后更新
- 6年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Genetically confirmed diagnosis of hereditary ataxia including diagnosis of spinocerebellar ataxia (any type) or Friedreich ataxia.
排除标准
- •No genetically confirmed diagnosis of spinocerebellar ataxia (any type) or genetically confirmed diagnosis of Friedreich ataxia. People with other progressive neurological disorders including Parkinson's disease, multiple sclerosis and Huntington's disease will not be included in this study.
结局指标
主要结局
未指定
相似试验
招募中
不适用
A phase 2 study of GX-I7 in combination with bevacizumab in recurrent glioblastoma (GBM) patientsNeoplasmsKCT0006561The Catholic University of Korea, Seoul St. Mary's Hospital20
进行中（未招募）
不适用
A trial investigating the efficacy of TKI258 in patients with cancer of the endometrium that has progressed after prior therapyEUCTR2011-000266-35-ESovartis Farmacéutica S.A80
进行中（未招募）
1 期
A trial investigating the efficacy of TKI258 in patients with cancer of the endometrium that has progressed after prior therapyTherapeutic area: Diseases [C] - Cancer [C04]Advanced and/or metastatic endometrial carcinomaMedDRA version: 20.0 Level: PT Classification code 10014736 Term: Endometrial cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000266-35-GBovartis Pharma Services53
进行中（未招募）
不适用
A trial investigating the efficacy of TKI258 in patients with cancer of theendometrium that has progressed after prior therapyAdvanced and/or metastatic endometrial carcinomaMedDRA version: 14.1Level: PTClassification code 10014736Term: Endometrial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-000266-35-ITOVARTIS FARMA80
进行中（未招募）
1 期
A phase II, multicentre, single-arm, open-label study of subcutaneoushomoharringtonine (HHT) alone in patients with accelerated phase chronicmyeloid leukemia (CML) who are refractory to, or have relapsed on imatinibmesylateEUCTR2005-000813-36-GBSTRAGEN France106